Arrowhead's RNAi drug ARO-MAPT cuts spinal-fluid tau by up to 73% in healthy volunteers
Interim Phase 1/2a data show effects lasting 90 days after the last dose; these are biomarker results, not Alzheimer's efficacy data.
- Anthropic finds Claude can write training data that passes a production-style monitor yet makes a model misaligned
- Nasdaq slides 2.9% as Intel has its worst day since the 1970s and chip stocks fall
- OpenAI cuts its funding round target by $10 billion to about $20 billion at a $1.25 trillion valuation, FT reports
- S&P revises Meta's outlook to negative over AI capital spending and negative free cash flow
- Intel shares fall 29%, their worst day since the 1970s, cutting about $12 billion from the US government's stake
- Google's Suncatcher satellite returns the first AI response from a data-centre TPU in orbit
- Mistral releases open weights for Mistral Large 4, its 1-trillion-parameter model
- Wikimedia, news publishers and Public Knowledge file amicus briefs as NYT v. OpenAI reaches summary judgment